Ultragenyx Pharmaceutical Expects Q3 Crysvita Revenue Of $74M-$76M And Dojolvi Revenue Of $16M-$17M
Portfolio Pulse from Benzinga Newsdesk
Ultragenyx Pharmaceutical expects Q3 revenue from Crysvita to be between $74M-$76M and Dojolvi revenue to be between $16M-$17M. The decrease in Crysvita revenue in the US was due to a decrease in channel inventory related to Kyowa Kirin Co's change from Ultragenyx labeled product to KKC’s labeled product.
October 16, 2023 | 12:17 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Ultragenyx Pharmaceutical expects a decrease in Q3 Crysvita revenue due to a change in channel inventory. However, the company expects inventories to normalize by the end of the year.
The decrease in Crysvita revenue due to a change in channel inventory could negatively impact Ultragenyx's Q3 earnings. However, the company expects inventories to normalize by the end of the year, which could mitigate the impact.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100